Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma.
Lonial S, Dimopoulos M, Palumbo A, et al. N Engl J Med, 373:621, Aug 2015
Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma. Lokhorst HM, Plesner T, Laubach JP,et al. N Engl J Med. 2015 Aug 26. [Epub ahead of print]
Proteasome inhibitors and immunomodulatory agents have improved survival in multiple myeloma. Now it appears that immunotherapy agents may provide more progress in the treatment of this disease. Elotuzumab (1), a monoclonal antibody targeting signaling lymphocytic activation molecule F7 and daratumumab (2), an antibody directed against CD38, showed encouraging results in patients with relapsed, refractory multiple myeloma. There are many other monoclonal antibodies in ongoing clinical testing.
Universidad Autonoma de Nuevo Leon, Hematology Service, Hospital Universitario Monterrey, México
E-Mail : dgomezalmaguer@gmail.com

This website is only for professional-level audience and health professionals
LookUs & Online Makale